|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||
| Depreciation and amortization of real estate, in-place lease, and other intangibles | |||||
| Stock-based compensation amortization expense | |||||
| Merger-related post-combination stock compensation expense | |||||
| Amortization of deferred financing costs and debt discounts (premiums) | |||||
| Straight-line rents | |||||
| Amortization of non-refundable entrance fees and above (below) market lease intangibles | |||||
| Amortization of above (below) market lease intangibles | |||||
| Amortization of non-refundable entrance fees | |||||
| Total amortization of non-refundable entrance fees and above (below) market lease intangibles | |||||
| Equity loss (income) from unconsolidated joint ventures | |||||
| Distributions of earnings from unconsolidated joint ventures | |||||
| Loss (gain) on sale of real estate under direct financing leases | |||||
| Deferred income tax expense (benefit) | |||||
| Impairments and loan loss reserves (recoveries), net | |||||
| Loss (gain) on debt extinguishments | |||||
| Loss (gain) on sales of real estate, net | |||||
| Loss (gain) upon change of control, net | |||||
| Casualty-related loss (recoveries), net | |||||
| Other non-cash items | |||||
| Changes in: | |||||
| Decrease (increase) in accounts receivable and other assets | |||||
| Increase (decrease) in accounts payable, accrued liabilities, and other liabilities | |||||
| Increase (decrease) in deferred revenue | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows from investing activities: | |||||
| Acquisitions of real estate | |||||
| Development, redevelopment, and other major improvements of real estate | |||||
| Leasing costs, tenant improvements, and recurring capital expenditures | |||||
| Proceeds from sales of real estate, net | |||||
| Proceeds from the South San Francisco JVs transaction, net | |||||
| Proceeds from the Callan Ridge JV transaction, net | |||||
| Investments in unconsolidated joint ventures | |||||
| Distributions in excess of earnings from unconsolidated joint ventures | |||||
| Proceeds from insurance recovery | |||||
| Proceeds from sales/principal repayments on loans receivable and other | |||||
| Investments in loans receivable and other | |||||
| Cash paid in connection with the Merger, net | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities: | |||||
| Borrowings under bank line of credit and commercial paper | |||||
| Repayments under bank line of credit and commercial paper | |||||
| Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt | |||||
| Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt | |||||
| Payments for deferred financing costs | |||||
| Issuance of common stock, net of offering costs | |||||
| Repurchase of common stock | |||||
| Dividends paid on common stock | |||||
| Distributions to and purchase of noncontrolling interests | |||||
| Contributions from and issuance of noncontrolling interests | |||||
| Net cash provided by (used in) financing activities | |||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash, beginning of year | |||||
| Cash, cash equivalents, and restricted cash, end of year | |||||
Loading...
